Hikma Pharmaceuticals Competitors

Hikma Pharmaceuticals (OTCMKTS:HKMPF) and ASSA ABLOY AB (publ) (OTCMKTS:ASAZY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Institutional & Insider Ownership

0.3% of ASSA ABLOY AB (publ) shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dividends

Hikma Pharmaceuticals pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. ASSA ABLOY AB (publ) pays an annual dividend of $0.14 per share and has a dividend yield of 0.9%. Hikma Pharmaceuticals pays out 10.7% of its earnings in the form of a dividend. ASSA ABLOY AB (publ) pays out 29.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Profitability

This table compares Hikma Pharmaceuticals and ASSA ABLOY AB (publ)'s net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Hikma Pharmaceuticals and ASSA ABLOY AB (publ)'s top-line revenue, earnings per share and valuation.

ASSA ABLOY AB (publ) has higher revenue and earnings than Hikma Pharmaceuticals. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than ASSA ABLOY AB (publ), indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Hikma Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, ASSA ABLOY AB (publ) has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Hikma Pharmaceuticals and ASSA ABLOY AB (publ), as provided by MarketBeat.com.

Summary

ASSA ABLOY AB (publ) beats Hikma Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Amadeus IT Group (OTCMKTS:AMADY) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) are both business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Valuation and Earnings

This table compares Amadeus IT Group and Hikma Pharmaceuticals' top-line revenue, earnings per share and valuation.

Amadeus IT Group has higher revenue and earnings than Hikma Pharmaceuticals. Amadeus IT Group is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amadeus IT Group and Hikma Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

0.2% of Amadeus IT Group shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Amadeus IT Group and Hikma Pharmaceuticals, as reported by MarketBeat.com.

Volatility and Risk

Amadeus IT Group has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Summary

Amadeus IT Group beats Hikma Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Hikma Pharmaceuticals (OTCMKTS:HKMPF) and CK Hutchison (OTCMKTS:CKHUY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Dividends

Hikma Pharmaceuticals pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. CK Hutchison pays an annual dividend of $0.13 per share and has a dividend yield of 1.6%. Hikma Pharmaceuticals pays out 10.7% of its earnings in the form of a dividend.

Analyst Recommendations

This is a summary of current ratings and target prices for Hikma Pharmaceuticals and CK Hutchison, as reported by MarketBeat.

Insider & Institutional Ownership

0.0% of CK Hutchison shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Hikma Pharmaceuticals and CK Hutchison's gross revenue, earnings per share and valuation.

CK Hutchison has higher revenue and earnings than Hikma Pharmaceuticals.

Volatility and Risk

Hikma Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, CK Hutchison has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.

Profitability

This table compares Hikma Pharmaceuticals and CK Hutchison's net margins, return on equity and return on assets.

Summary

CK Hutchison beats Hikma Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

Swire Pacific (OTCMKTS:SWRAY) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) are both transportation companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Institutional & Insider Ownership

0.1% of Swire Pacific shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Swire Pacific has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Earnings and Valuation

This table compares Swire Pacific and Hikma Pharmaceuticals' gross revenue, earnings per share and valuation.

Swire Pacific has higher revenue and earnings than Hikma Pharmaceuticals. Swire Pacific is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Dividends

Swire Pacific pays an annual dividend of $0.23 per share and has a dividend yield of 2.9%. Hikma Pharmaceuticals pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. Swire Pacific pays out 9.2% of its earnings in the form of a dividend. Hikma Pharmaceuticals pays out 10.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Swire Pacific is clearly the better dividend stock, given its higher yield and lower payout ratio.

Analyst Ratings

This is a summary of current recommendations and price targets for Swire Pacific and Hikma Pharmaceuticals, as reported by MarketBeat.

Profitability

This table compares Swire Pacific and Hikma Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Swire Pacific beats Hikma Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Fujitsu (OTCMKTS:FJTSY) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) are both computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

0.1% of Fujitsu shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Fujitsu has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.

Valuation & Earnings

This table compares Fujitsu and Hikma Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Fujitsu has higher revenue and earnings than Hikma Pharmaceuticals. Fujitsu is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Dividends

Fujitsu pays an annual dividend of $0.28 per share and has a dividend yield of 0.9%. Hikma Pharmaceuticals pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. Fujitsu pays out 19.3% of its earnings in the form of a dividend. Hikma Pharmaceuticals pays out 10.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Analyst Recommendations

This is a breakdown of current ratings for Fujitsu and Hikma Pharmaceuticals, as reported by MarketBeat.

Profitability

This table compares Fujitsu and Hikma Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Fujitsu beats Hikma Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Hikma Pharmaceuticals (OTCMKTS:HKMPF) and Ashtead Group (OTCMKTS:ASHTY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings.

Volatility & Risk

Hikma Pharmaceuticals has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Ashtead Group has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.

Profitability

This table compares Hikma Pharmaceuticals and Ashtead Group's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for Hikma Pharmaceuticals and Ashtead Group, as provided by MarketBeat.com.

Dividends

Hikma Pharmaceuticals pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. Ashtead Group pays an annual dividend of $0.69 per share and has a dividend yield of 0.3%. Hikma Pharmaceuticals pays out 10.7% of its earnings in the form of a dividend. Ashtead Group pays out 7.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Valuation & Earnings

This table compares Hikma Pharmaceuticals and Ashtead Group's revenue, earnings per share (EPS) and valuation.

Ashtead Group has higher revenue and earnings than Hikma Pharmaceuticals. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than Ashtead Group, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

0.8% of Ashtead Group shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Ashtead Group beats Hikma Pharmaceuticals on 12 of the 14 factors compared between the two stocks.